Key Highlights

• Ceretas develops a portable, image-guided therapeutic ultrasound platform.

• The technology targets Alzheimer's disease and other neurodegenerative conditions.

• The company listed on the ASX in July 2026 and raised about AUD 8mn.

• Ceretas remains pre-revenue and focused on clinical validation.

Ceretas (ASX:CTS) is advancing a portable, image-guided therapeutic ultrasound platform after listing on the ASX in July 2026 and raising about AUD 8mn.

Company Business

Ceretas is developing a therapeutic ultrasound device intended to deliver focused, image-guided treatment in a portable form. The company originated from technology commercialised through the University of Queensland's commercialisation arm.

Sector Context

Therapeutic ultrasound for neurodegenerative disease is an emerging field. Novel medical devices must progress through technical validation, clinical development and regulatory processes before commercial adoption.

Risks to Consider

Ceretas is pre-revenue and at an early stage. Clinical outcomes, regulatory requirements, funding needs and the ability to establish commercial partnerships can materially affect the development pathway.

What to Watch Next

Clinical progress, regulatory engagement, partnerships and funding are the main indicators of advancement. These milestones are more informative for the Business than short-term trading activity.